

Date: -April 15, 2023

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited,</b> Exchange Plaza, C-1, Block – G, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, <b>BSE Limited,</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001.
<b>Scrip Code – LINCOLN</b>	<b>Scrip Code – 531633</b>

Dear Sir/Ma'am,

**Sub: Initial Large Corporate Disclosure - FY 2023-24**

**Ref: SEBI Circular No: SEBI/HO/DDHS/P/CIR/2021/613 dated April 13, 2022**

With reference to the above circular, we wish to inform that, our Company does not fall under the category of Large Corporates (LC) as on 31st March 2023, as per the framework provided in the said Circular since the specified criteria are not applicable to us.

The undertaking as required under the said circular is enclosed as ("**Annexure -A**").

This is for your information and records.

Thanking you,

**For, Lincoln Pharmaceuticals Limited,**

**For, Lincoln Pharmaceuticals Limited,**

**Trusha Shah**  
**Company Secretary & Compliance Officer**

**Darshit Shah**  
**Chief Financial Officer**

Encl.: As Above

**Regd. Office :** "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India  
**Phone :** +91-79-4107 8000 | **Fax :** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288  
**E-mail :** info@lincolnpharma.com | **Website :** www.lincolnpharma.com

**Factory :** 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

**Ta. :** Kalol, Dist. Gandhinagar, (Guj.) | **Phone :** +91-79-49135000 | **E-mail :** khatraj@lincolnpharma.com



**Annexure - A**

**Initial Disclosure to be made by an entity identified as a Large Corporate to be submitted to the Stock Exchange(s) within 30 days from the beginning of the FY 2023-24)**

<b>SI. No</b>	<b>Particulars</b>	<b>Details</b>
<b>1.</b>	Name of the company	Lincoln Pharmaceuticals Limited
<b>2.</b>	CIN	L24230GJ1995PLC024288
<b>3.</b>	Outstanding borrowing of company as on 31st March (in Rs. crore)	Not applicable
<b>4.</b>	Highest credit rating during the previous FY along with name of the CRA	Not applicable
<b>5.</b>	Name of stock exchange in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	Not applicable

We confirm that we are not a Large Corporate as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021 and April 13, 2022.

Thanking you,

**For, Lincoln Pharmaceuticals Limited,**

**For, Lincoln Pharmaceuticals Limited,**

**Trusha Shah**  
**Company Secretary & Compliance Officer**  
**Contact Details: 079-41078081**

**Darshit Shah**  
**Chief Financial Officer**  
**Contact Details: 079-41078048**

**Date: April 15, 2023**